Vancouver, BC / ACCESSWIRE / August 8, 2014 / Vodis Pharmaceuticals Inc. (the "Company" or "Vodis") (CSE: VP FSE: 1JV) is pleased to announce that it has listed its common shares on the Frankfurt Stock Exchange (FWB) under the ticker symbol "1JV " and the International Securities Identification Number (ISIN): CA92858L1031. The Frankfurt Stock Exchange is the world's third-largest (behind only the Nasdaq Stock Market and New York Stock Exchange) organized exchange-trading market in terms of turnover and dealings in securities. The Company's shares continue to trade on the Canadian Securities Exchange as the primary market.
Otto Folprecht, CEO & Director states: "The listing on the Frankfurt stock exchange will help to increase Vodis Pharmaceuticals' trading liquidity and facilitate investment in the company by European investors."
Vodis is one of Canada's foremost brand names in the medical marijuana business. Our products have consistently won or placed at each competition we have entered. The company is in the application process to become a Licenced Producer at our 12,000 square foot facility in Canada.
We seek Safe Harbor.
For further information please contact:
CFO & Director
104-1037 West Broadway
Vancouver, BC V6H 1E3
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of Newnote Financial Corp. The forward-looking information is based on certain key expectations and assumptions made by the company's management. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE: Vodis Pharmaceuticals Inc.